Skip to main content

Table 1 Main characteristics of studies included in the meta-analysis

From: Prognostic value of neuron-specific enolase for small cell lung cancer: a systematic review and meta-analysis

Study

Year

Study design

Ethnicity

N

Percentage of LD-SCLC

Percentage of male patients

Age (median)

Age (mean)

Age (range)

Cutoff of NSE (ng/ml)

Treatment

Outcome

NOS

van der Gaast A [25]

1991

Retrospective

Caucasian

70

41.4%

77.1%

63

 

36–75

12.5

C

OS

7

Johnson PW [26]

1993

Retrospective

Caucasian

154

29.2%

65.0%

63

 

34–77

25

C,R

OS

7

Fischer JR [27]

1997

Retrospective

Caucasian

52

63.5%

75.0%

 

58

36–75

30

C,R

OS

6

Shibayama T [28]

2001

Retrospective

Asian

114

59.1%

86.8%

65

 

29–82

7.5

C,R

OS

6

Jin B [29]

2001

Retrospective

Asian

144

NA

85.4%

62.12

 

36–86

12.5

C

OS

6

Jean-Louis Pujol [30]

2003

Retrospective

Caucasian

148

39.2%

93.9%

63

61

42–82

17

C,R

OS

7

Bremnes RM [31]

2003

Prospective

Caucasian

436

49.1%

64.2%

64

 

39–76

13

C,R

OS

7

Ando S [32]

2004

Retrospective

Asian

57

64.9%

84.2%

 

66

48–78

10.5

S,C,R

OS

6

Xue F [33]

2011

Retrospective

Asian

57

52.6%

68.4%

52.5

 

29–70

15.2

C,R

OS

6

Zhu H [34]

2015

Retrospective

Asian

281

55.5%

80.4%

57

 

25–82

18

S,C,R

OS

7

Huang Z [21]

2016

Retrospective

Asian

122

44.3%

75.4%

NA

NA

NA

17

C,R

PFS

6

Wojcik E [35]

2016

Retrospective

Caucasian

63

65.1%

60.3%

59

 

32–76

35

C,R

OS

6

Jiang X [36]

2017

Retrospective

Asian

107

39.3%

78.5%

63

 

58.5–68

17

C,R

OS

7

Pan H [37]

2017

Retrospective

Asian

275

NA

87.0%

 

62.59

 

81.4

C,R

OS

7

Zhou M [38]

2017

Retrospective

Asian

523

26.8%

79.3%

59

 

27–87

 

C,R

OS

7

Liu X [39]

2017

Prospective

Asian

136

43.4%

64.7%

 

53.3

 

50.324

C,R

OS, PFS

6

Zhang C [40]

2018

Retrospective

Asian

160

23.8%

80.6%

59

 

23–83

 

C

PFS

7

Fan S [41]

2019

Retrospective

Asian

82

NA

81.7%

60

 

28–82

16.3

C,R

OS, PFS

7

  1. Abbreviations: LD-SCLC limited disease small cell lung cancer, C chemotherapy, R radiotherapy, S surgery, OS overall survival, PFS progression-free survival, NA not available